Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Pharming Group N.V.

Teva vs. Pharming: Divergent Cost Strategies in Pharma

__timestampPharming Group N.V.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201441672749216000000
Thursday, January 1, 201552478518296000000
Friday, January 1, 2016492511810044000000
Sunday, January 1, 20171493029711560000000
Monday, January 1, 20182537176810558000000
Tuesday, January 1, 2019239212749351000000
Wednesday, January 1, 2020253382368933000000
Friday, January 1, 2021201829668284000000
Saturday, January 1, 2022175620007952000000
Sunday, January 1, 2023252120008200000000
Monday, January 1, 20248480000000
Loading chart...

Cracking the code

Cost of Revenue Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Teva Pharmaceutical Industries Limited and Pharming Group N.V. present a fascinating study in contrasts. From 2014 to 2023, Teva's cost of revenue has shown a gradual decline, dropping approximately 14% from its peak in 2017. This trend reflects Teva's strategic cost management amidst a challenging market landscape. Meanwhile, Pharming Group N.V. has experienced a dramatic rise, with costs increasing over 500% during the same period. This surge highlights Pharming's aggressive expansion and investment in new product lines. The data underscores the diverse strategies employed by these companies to navigate the competitive pharmaceutical sector. As Teva focuses on efficiency, Pharming bets on growth, offering a compelling narrative of adaptation and ambition in the face of industry challenges.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025